Monopar Therapeutics Inc. MNPR
85.24
(3.60)
(4.05%)
as of 25 Sep
- Market cap
- $602.8M
- P/E
- 0.0×
Follow MNPR
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(26.54%) | (14.22%) | (15.86%) | (19.50%) | |
| (25.88%) | (13.65%) | (15.52%) | (18.90%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(13.74%) | (9.96%) | (11.08%) | (13.65%) | |
Free Cash Flow per Share |
(1.52) | (1.65) | (1.17) | (1.43) | |
Free Cash Flow |
(10.83) | (12.20) | (10.01) | (12.18) | |
Piotroski F-Score |
3.00 | 3.00 | 3.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(3.80%) | (4.39%) | (3.67%) | (4.59%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.56 | 0.89 | 0.67 | 0.68 | |
Depreciation/Fixed assets |
— | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.52) | (1.65) | (1.17) | (1.43) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates